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Introduction. Diagnosis of breast cancer at its early stage influences significantly long-term treatment outcomes in 
patients. As result, more often application of breast-conserving surgical procedures becomes possible. This paper 
presents our centre’s up-to-date experiences in this field.
Materials and methods. 12,337 patients diagnosed with primary malignant neoplasm of the breast surgically treated 
at the Oncology Centre in Bydgoszcz between 2002 and 2017. Analysis of applied breast-conserving procedures in 
the analysed group.
Results. Observation of consecutive years indicates over double increase in the number of patients (498 in 2002, 1136 
in 2017). Breast-conservative treatment (BCT) was recorded in 10.6% of patients (2002) and 65.1% in 2017. Treatment 
sparing lymph nodes of the axillary fossa concerned 2.2–79.0% in the analyzed period.
Conclusions. In the analyzed time period, we recorded a significant increase in the number of surgical BCT procedures 
applied. It was possible due to regular introduction of changes regarding diagnostic and therapeutic algorithms to 
our everyday clinical practice in patients suffering from malignant breast neoplasms. 
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Introduction 
A cancer diagnosis at an early stage of the disease can 
influence significantly a long-term treatment outcome in 
patients. Additionally, particularly in breast cancer patients, 
early discovery of lesions allows for more frequent use of 
sparing surgical procedures [1, 2]. Depending on the cancer 
stage initially found, they can involve local radical resection of 
the mass with radiotherapy supplementing the surgery (BCT). 
This may also refer to structures of the regional lymphatic 
system — by using the sentinel lymph node biopsy (SLNB).
The surgical procedures listed above belong to treat-
ment methods commonly used in patients [1, 2]. Their ef-
fectiveness and safety of use were proven by many years 
of monitoring in groups of patients enrolled into source 
studies [3, 4]. They are also confirmed by results of successive 
randomised clinical studies [5–7].
The most important objective of sparing treatment used 
in breast cancer patients is the maximum effectiveness of 
the cancer therapy. However, attempting to limit adverse 
effects of cancer treatment is also of great importance. For 
BCT, the priority in that respect is that patients avoid unde-
sirable changes related to a loss of a breast [1–6]. However, 
a possibility of performing SLNB allows for avoiding com-
plications characteristic for axillary lymphadenectomy (or 
significant reduction in their intensity). The most important 
clinical problems include lymphatic swelling of the upper 
limb on the treated side, sensory disturbances, disrupted 
motor function in relevant muscles (as a consequence of 
the peripheral nervous system damage) and post-surgery 
deformation of integuments [7, 8].
Apart from the current treatment standard for breast 
cancer patients, the extent to which BCT and SLNB pro-
4cedures are used in individual oncology centres may also 
depend, though to a much lesser extent, on local equipment 
and technical resources. A type and level of medical person-
nel education, as well as their individual preferences, also 
appear to be of importance [9–11].
This study aims at discussing application of sparing sur-
gical procedures in patients with breast cancer, hospitalised 
at our centre. The reasons for the changes in the method of 
qualification of patients for both types of surgical procedu-
res were determined. Furthermore, clinical consequences of 
modifications introduced in this area were also evaluated, 
visible at individual intervals of the analysed period.
Material and methods
A group of 12,337 patients (12,278 women, 59 men) 
diagnosed with primary breast cancer, hospitalised at the 
Breast Cancer and Reconstructive Surgery Clinical Unit and 
at the Surgical Oncology Clinical Unit, Oncology Centre in 
Bydgoszcz, in 2002–2017. All patients underwent surgical 
treatment, in most cases of radical nature.
The study was conducted in the form of a retrospective 
analysis, in which clinical data from patients digital medical 
records were used. 
For purposes of statistical comparisons, a group of 
patients was distinguished in the analysed clinical mate-
rial, in whom sparing surgical procedures were used. The 
group of patients who underwent BCT included cases, in 
which initially planned breast-conservative treatment was 
not changed. Therefore, patients who eventually required 
mastectomy resulting from the need for more radical treat-
ment following initially performed BCT, were not included 
in this group.
The group of patients undergoing the treatment spa-
ring axillary lymph nodes included patients qualified for 
the SLNB procedure. It did not include cases of cancers 
not requiring verification of the axillary lymphatic system 
(patients diagnosed with cancer of mesenchymal origin 
and some patients with ductal carcinoma in situ — DCIS) 
or treated in non-radical way (patients undergoing salva-
ge mastectomy). Apart from determining the number of 
subjects in the group, a percentage of metastatic lesions 
found in resected lymph nodes was also analysed. The size 
and type of metastases were classified according to the 
classification established by the American Joint Committee 
on Cancer (AJCC) [12].
Due to significant modifications of treatment recom-
mendations for patients with metastases in sentinel nodes, 
observed during the study, this clinical problem was not 
analysed separately.
During the patient qualification for specific surgical pro-
cedures, commonly available recommendations on surgi-
cal treatment of breast cancer published by national and 
international scientific associations were used [3, 4, 13–18]. 
In order to determine the reasons for the changes in the 
method of qualification of patients to particular types of sur-
gical procedures, we estimated the extent of use of neoadju-
vant systemic treatment/induction therapy and pre-operative 
diagnosis based on screening tests in investigated patients.
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Figure 1. Use of breast-conservative treatment (BCT) in the analysed group of patients (2002–2017)
5Results
In the successive years of follow-up, it was found that 
the number of patients requiring surgical treatment due to 
breast cancer more than doubled. The number of patients 
hospitalised for this reason was 498 in 2002, 852 in 2010 and 
1136 in 2017 (with the overall increase in the number of ca-
ses throughout the analysed period by 128%). The complete 
data for the analysed period has been provided in Figure 1.
The differences were much larger for the frequency of 
use of sparing surgical procedures in the analysed group. For 
BCT, this procedure was performed in every tenth patient 
(10.6%) undergoing surgery in 2002. In 2017, this surgical 
procedure was performed in 65.1% of breast cancer patients 
(Fig. 1). In total, BCT was performed in 5391 patients, and 
the average use of this procedure reached 43.7% for the 
whole analysed period. 
The surgical treatment sparing the axillary lymphatic 
system started being used at our centre slightly later than 
BCT (since 2004). 5446 patients in total were qualified for the 
sentinel lymph node biopsy. In the first year, it was conduc-
ted in 11 patients (representing 2.2% of all patients treated 
surgically), while in the last year of the observation, 79.0% 
(897/1136) of patients were qualified for SLNB — Figure 2.
In 1282 (23.5%) patients undergoing SLNB, presence of 
metastases was found in resected lymph nodes. They were 
not observed during the first three years of this procedure’s 
use (2004–2006). This resulted from the fact that the lymph 
node sparing procedure was used in patients with ductal 
carcinoma in situ requiring simple amputation. In successive 
years of analysis, the percentage of patients with axillary 
metastases qualified for SLNB ranged from 18.3–25.5%, 
reaching the highest value in 2011 (Table I).
Within analyzed time frames significant differences in 
the extent of neoadjuvant systemic treatment (and induc-
tion therapy) use in patients were observed. In year of 2002, 
7.6% patients who underwent surgical procedure, 2006 — 
13.2% and 2011 — 9.8%, however in 2017 — 19.9% were 
qualified for such treatment. 
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Figure 2. Patients qualified for the axillary conserving treatment (SLNB) — 2002–2017
Table I. Patients qualified for sentinel lymph node biopsy
Period Patients 
qualified for 
SLNB 
(n = 5446)
Patients 
with axillary 
metastases  
(n = 1282)
Percentage 
of axillary 
metastases  
(%)
2004 11 0 0.0%
2005 5 0 0.0%
2006 1 0 0.0%
2007 14 3 21.4%
2008 100 20 20.0%
2009 180 33 18.3%
2010 266 64 24.1%
2011 494 126 25.5%
2012 592 137 23.1%
2013 629 152 24.2%
2014 687 159 23.1%
2015 761 163 21.4%
2016 809 199 24.6%
2017 897 226 25.2%
Total 5446 1282 23.5 %
6The existence of similar discrepancies was noted in the 
percentage of patients, whose diagnosis of breast cancer 
subjected them to screening mammography. In 2006 this 
situation occurred in 16.2% of operated patients, in 2011 
— 39.5% and in 2017 — 30.7%.
Discussion
In the conducted analysis, observations performed at 
our centre and concerning the use of BCT and SLNB pro-
cedures were presented. As the analysis covered a long 
period of several years and a very large number of patients, 
a complete and extensive analysis of this important issue 
was possible. In the available Polish reports, analyses at the 
similar scale are not frequently attempted [19–22].
As the presented data imply, significant changes occur-
red in frequency of use of both types of sparing procedures. 
Currently, both BCT and SLNB are most commonly used 
surgical procedures, out of surgical treatment options ava-
ilable to patients.
One of the key reasons for an increase in a rate of the 
breast-conservative treatments was a fact that a number 
of relative contraindications to BCT were no longer taken 
into account. In some cases, these limitations were of clearly 
historical importance (for example, a patient with a history of 
breast cancer involving the other breast or of other primary 
cancer, primary cancer of comedo type).
The most important reason for an increase in BCT use 
were clinical outcomes achieved with the implemented 
screening population programme aiming at early breast 
cancer diagnosis using screening mammography. This rela-
tionship is confirmed by results of many studies, including 
those conducted at our centre [23–25]. Apart from the main 
objective for performing screening tests — a reduced risk of 
breast cancer mortality (even by 30–32%), frequently a new 
case can be diagnosed in a period preceding development 
of the first clinical symptoms [25, 26]. This facilitates more 
frequent use of breast-conservative treatment.
An important factor supporting the increase in the num-
ber of patients undergoing BCT was also the increasing 
percentage of patients with resected breast masses qualified 
for neoadjuvant therapy. In some patients this helped to 
avoid amputation. In accordance with the current standard 
for breast cancer treatment, a possibility to apply the bre-
ast-conservative treatment for multiple lesions was also of 
importance [16, 17, 27].
Even greater changes were noted for a percentage of 
patients qualified at our centre for the treatment sparing 
axillary lymph nodes. As it was noted before, it raised from 
the level of 2.2% to 79.0% in the analysed period. The SLNB 
procedure was initially used to supplement the simple am-
putation performed for extensive lesions of DCIS nature. A 
gradual extension of indications for the sentinel node resec-
tion (also as a part of the so-called learning curve) led to the 
widespread use of SLNB in patients with invasive forms of 
breast cancer. A prerequisite for this procedure was a lack 
of suspicious axillary lymph nodes (in clinical evaluation 
and diagnostic imaging scans) in patients. However, when 
anomalies were found in physical examination (in the form 
of enlarged lymph nodes), concurring with lesions shown in 
ultrasound scans, the patients underwent effective axillary 
lymphadenoctomy.
Achieving the current percentage of patients qualified 
for the SLNB was possible thanks to taking into account the 
current recommendations for this procedure, presented by 
the National Consultant for surgical oncology. In accordance 
with these recommendations, “finding (by palpation or in 
imaging scans) single, clinically suspicious lymph nodes 
does not authorise use of axillary lymphadenctomy, but it 
necessitates their verification (fine-needle aspiration)” [18]. 
Thus a decision not to perform treatment sparing axillary 
lymph nodes is justified when metastases are found in them 
before the surgery. In other cases, SLNB procedure is requ-
ired, and currently nearly 80% of breast cancer patients are 
qualified for this procedure at our centre. 
Besides the evaluation of a frequency of the SLNB proce-
dure in the analysed period, it was also necessary to present 
direct clinical consequences of the implemented changes. 
To this end, it was necessary to decide whether the incre-
asing number of patients qualified for SLNB results in a 
comparable increase in a number of breast cancer meta-
stases to lymph nodes. The greatest raise in the percentage 
of metastases found in the sentinel node accompanied 
the extension of indications for SLNB to metastatic lesions 
exceeding 3 cm (masses at the clinical stage cT2 > 3 cm 
and cT3) and to patients with multiple lesions (2011–2012). 
This is consistent with results of other studies, in which it 
was confirmed that in breast cancer patients the size of the 
primary mass is one of the most important factors increasing 
a risk for metastases found in the lymphatic system [7, 9, 14]. 
Another modification of rules for qualifying patients for the 
sentinel node resection (according to the National Consul-
tant recommendations [18]) did not lead to further increase 
in the overall number of metastases to lymph nodes.
Regardless of the gradual extension of recommenda-
tions for the SLNB procedure, other causes were decisive 
for additional use of treatment sparing the axillary lym-
phatic system, too. Its use was also possible in strictly 
defined groups of patients with metastatic lesions in the 
sentinel node. According to international experts’ recom-
mendations, in specific clinical situations, a withdrawal 
from the auxiliary axillary lymphadenoctomy is currently 
the standard procedure [16]. This is confirmed by our earlier 
studies, in which complete safety of implementation of 
the above changes was demonstrated [28–30]. However, a 
comprehensive discussion of them exceeds the framework 
of this study.
7Conclusions
With a systematic implementation of changes in diagno-
stic and therapeutic procedures in breast cancer patients in 
daily clinical practice, it was possible to increase significantly 
the rate of use of sparing surgical procedures. The expec-
ted result of that situation is a reduction in frequency and 
intensity of adverse effects of cancer treatment. However, 
a complete evaluation of this issue requires more extensive 
analyses.
As it was demonstrated additionally, only detailed know-
ledge of currently applicable diagnostic and treatment rules 
concerning breast cancer patients enables selection of the 
optimal cancer treatment. This also applies to the use of 
surgical procedures.
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